Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]

The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate...

Full description

Bibliographic Details
Main Authors: Veljko Veljkovic, Philippe M. Loiseau, Bruno Figadere, Sanja Glisic, Nevena Veljkovic, Vladimir R. Perovic, David P. Cavanaugh, Donald R. Branch
Format: Article
Language:English
Published: F1000 Research Ltd 2015-02-01
Series:F1000Research
Subjects:
Online Access:http://f1000research.com/articles/4-34/v1
id doaj-54313bb2893248b4bd68565fbbb7dc69
record_format Article
spelling doaj-54313bb2893248b4bd68565fbbb7dc692020-11-25T03:50:03ZengF1000 Research LtdF1000Research2046-14022015-02-01410.12688/f1000research.6110.16544Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]Veljko Veljkovic0Philippe M. Loiseau1Bruno Figadere2Sanja Glisic3Nevena Veljkovic4Vladimir R. Perovic5David P. Cavanaugh6Donald R. Branch7Center for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaAntiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry, FranceAntiparasitic Chemotherapy, UMR 8076 CNRS BioCIS, Faculty of Pharmacy Université Paris-Sud, Rue Jean-Baptiste Clément, F 92290- Chatenay-Malabry, FranceCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaCenter for Multidisciplinary Research, University of Belgrade, Institute of Nuclear Sciences VINCA, P.O. Box 522, 11001 Belgrade, SerbiaBench Electronics, Bradford Dr., Huntsville, AL, 35801, USACanadian Blood Services, Center for Innovation, 67 College Street, Toronto, Ontario, M5G 2M1, CanadaThe ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.http://f1000research.com/articles/4-34/v1Antimicrobials & Drug ResistanceBioinformaticsTropical & Travel-Associated DiseasesVirology
collection DOAJ
language English
format Article
sources DOAJ
author Veljko Veljkovic
Philippe M. Loiseau
Bruno Figadere
Sanja Glisic
Nevena Veljkovic
Vladimir R. Perovic
David P. Cavanaugh
Donald R. Branch
spellingShingle Veljko Veljkovic
Philippe M. Loiseau
Bruno Figadere
Sanja Glisic
Nevena Veljkovic
Vladimir R. Perovic
David P. Cavanaugh
Donald R. Branch
Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
F1000Research
Antimicrobials & Drug Resistance
Bioinformatics
Tropical & Travel-Associated Diseases
Virology
author_facet Veljko Veljkovic
Philippe M. Loiseau
Bruno Figadere
Sanja Glisic
Nevena Veljkovic
Vladimir R. Perovic
David P. Cavanaugh
Donald R. Branch
author_sort Veljko Veljkovic
title Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
title_short Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
title_full Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
title_fullStr Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
title_full_unstemmed Virtual screen for repurposing approved and experimental drugs for candidate inhibitors of EBOLA virus infection [v1; ref status: indexed, http://f1000r.es/51s]
title_sort virtual screen for repurposing approved and experimental drugs for candidate inhibitors of ebola virus infection [v1; ref status: indexed, http://f1000r.es/51s]
publisher F1000 Research Ltd
series F1000Research
issn 2046-1402
publishDate 2015-02-01
description The ongoing Ebola virus epidemic has presented numerous challenges with respect to control and treatment because there are no approved drugs or vaccines for the Ebola virus disease (EVD). Herein is proposed simple theoretical criterion for fast virtual screening of molecular libraries for candidate inhibitors of Ebola virus infection. We performed a repurposing screen of 6438 drugs from DrugBank using this criterion and selected 267 approved and 382 experimental drugs as candidates for treatment of EVD including 15 anti-malarial drugs and 32 antibiotics. An open source Web server allowing screening of molecular libraries for candidate drugs for treatment of EVD was also established.
topic Antimicrobials & Drug Resistance
Bioinformatics
Tropical & Travel-Associated Diseases
Virology
url http://f1000research.com/articles/4-34/v1
work_keys_str_mv AT veljkoveljkovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT philippemloiseau virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT brunofigadere virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT sanjaglisic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT nevenaveljkovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT vladimirrperovic virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT davidpcavanaugh virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
AT donaldrbranch virtualscreenforrepurposingapprovedandexperimentaldrugsforcandidateinhibitorsofebolavirusinfectionv1refstatusindexedhttpf1000res51s
_version_ 1724492633192005632